Peng et al. reported that IGFBP-3 may contribute to androgen-induced antiproliferative effects in LNCaP human prostate cancer cells through increasing CDK1, P21, and P27, leading to G1 arrest30. Here, CDK1 is linked to prostate carcinoma.